Esperion Therapeutics' aggressive commercialization efforts have significantly boosted retail prescriptions and broadened ...

Analyst Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Regulus (RGLS – Research Report) and keeping the price target at ...

Axsome Therapeutics surpassed revenue expectations in Q3, driven by strong sales from its key products.

Mizuho Securities analyst Graig Suvannavejh has maintained their bullish stance on AXSM stock, giving a Buy rating on November 8. Graig ...

Viking Therapeutics (NASDAQ: VKTX) soared to center stage earlier this year as a potentially promising player in one of today ...

Below, I'll break down what's going on at Viking and explain how the company may emerge as a competitive force in the weight ...

Sangamo Therapeutics ranks at the bottom for Revenue Growth and Gross Profit, indicating lower performance compared to its peers. However, it ranks in the middle for Return on Equity, suggesting ...

PTC Therapeutics' gene therapy is already approved in the European ... while European stocks rose on hopes of a better growth ...

As per Deloitte, inflation in the Eurozone slightly rebounded in October but was still quite low. The consumer price index ...

Analysts have set 12-month price targets for Dianthus Therapeutics, revealing an average target of $46.0, a high estimate of ...

TG Therapeutics' Q3 earnings missed EPS expectations despite Briumvi's revenue growth. See why TGTX stock is a Buy.

During the third quarter, TG Therapeutics boosted Briumvi's market penetration, driving U.S. net revenue up by over 230% year ...